Compare W W Grainger Inc (GWW) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Novo Nordisk A/S — how do they compare? W W Grainger Inc trades at $1,291.99 (market cap $59.76B), while Novo Nordisk A/S trades at $38.44 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.8× W W Grainger Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and Novo Nordisk A/S for 116 Days on average.
| GWW | NVO | |
|---|---|---|
Market Cap | $59.76B | $165.31B |
Volume | 186,697 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $1.40K | $63.98 |
52-Week Low | $918.18 | $35.29 |
Typical Hold Time | 25 Days | 116 Days |
Enterprise Value | $61.96B | $179.56B |
Dividend Yield | 0.79% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,263.51, down 0.94% on the day, amid a bearish technical signal. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. The company maintains strong profitability with a net income margin of 9.92% and ROE of 47.92%, though valuation ratios like P/E of 32.34 appear elevated. Recent news highlights institutional buying and expansion efforts, including a new distribution center in Oregon and the acquisition of technology assets from Adroit Worldwide Media.
The outlook for GWW is cautiously optimistic, supported by earnings beats and solid fundamentals, but risks include high valuation and competitive pressures. Analyst consensus leans hold with a $1,310 price target, suggesting limited upside. Investors should weigh strong cash flow and dividend consistency against potential margin compression and market volatility.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
